



**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 21 to 36 of 2022**

Statements of Principles Nos. 21 to 36 of 2022 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 4 March 2022. The day of commencement as specified in each of these Instruments is 4 April 2022.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from <http://www.legislation.gov.au>.

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on the Authority's website at <http://www.rma.gov.au>.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is also available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar  
Repatriation Medical Authority  
GPO Box 1014  
Brisbane Qld 4001

T +61 7 3815 9404  
F +61 7 3815 9412  
E [info@rma.gov.au](mailto:info@rma.gov.au)

16 March 2022

## SUMMARY OF CHANGES

Instr. No.	Title	Date of Commencement	ICD-10-AM Code
<b>REPEALS</b>			
21 & 22/2022	hypertension	4/04/2022	I10, I15
23 & 24/2022	heart block	4/04/2022	I44, I45.0, I45.1, I45.2, I45.3, I45.4, I45.9
25 & 26/2022	periodontal abscess	4/04/2022	Nil
27 & 28/2022	periodontitis	4/04/2022	K05.3
<b>DETERMINATIONS</b>			
29 & 30/2022	eosinophilic oesophagitis	4/04/2022	Nil
31 & 32/2022	exertional heat illness	4/04/2022	T67.0, T67.1, T67.2, T67.3, T67.4, T67.5
33 & 34/2022	vaccine-induced thrombotic thrombocytopenia	4/04/2022	Nil
<b>AMENDMENTS</b>			
35 & 36/2022	suicide and attempted suicide	4/04/2022	Nil

Note:

1. The investigation concerning 'heat stroke' has resulted in the determination of Statements of Principles concerning **exertional heat illness**.
2. The investigation concerning 'thrombosis with thrombocytopenia syndrome' has resulted in the determination of Statements of Principles concerning **vaccine-induced thrombotic thrombocytopenia**.

**SUMMARY OF CHANGES**21 &  
22/2022

hypertension

These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 29 March 2021 concerning *hypertension* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

**For RH SoP (Instrument No. 21/2022)**

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'hypertension' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factors in subsections 9(1) and 9(26) concerning being overweight or obese;
- revising the factors in subsections 9(2) and 9(27) concerning consuming alcohol;
- revising the factors in subsections 9(3) and 9(28) concerning consuming salt;
- revising the factors in subsections 9(4) and 9(29) concerning having renal artery stenosis;
- revising the factors in subsections 9(5) and 9(30) concerning having a solid organ, stem cell or bone marrow transplant;
- new factors in subsections 9(6) and 9(31) concerning having diabetes mellitus;
- revising the factors in subsections 9(7) and 9(32) concerning having chronic kidney disease;
- revising the factors in subsections 9(8) and 9(33) concerning having an endocrine disorder;
- revising the factors in subsections 9(9) and 9(34) concerning having sleep apnoea;
- revising the factors in subsections 9(11) and 9(36) concerning having an aneurysm of the renal artery, an arteriovenous fistula involving the blood supply of the kidney, or an arteriovenous malformation involving the blood supply of the kidney;
- revising the factors in subsections 9(12) and 9(37) concerning having a clinically significant disorder of mental health as specified;
- new factors in subsections 9(13) and 9(38) concerning having gout or hyperuricaemia;
- revising the factors in subsections 9(14) and 9(39) concerning taking a drug from the Schedule 2 – Drugs;
- revising the factors in subsections 9(15) and 9(40) concerning taking a drug from the Specified List 1 of drugs;
- revising the factors in subsections 9(16) and 9(41) concerning having glucocorticoid therapy;
- new factors in subsections 9(17) and 9(42) concerning taking medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection;
- revising the factors in subsections 9(18) and 9(43) concerning inability to undertake any physical activity greater than 3 METs;
- revising the factors in subsections 9(19) and 9(44) concerning being exposed to arsenic, by the inclusion of a note;
- new factors in subsections 9(20) and 9(45) concerning undergoing a course of therapeutic radiation for cancer;
- new factors in subsections 9(21) and 9(46) concerning having received a cumulative equivalent dose of ionising radiation;
- revising the factors in subsections 9(22) and 9(47) concerning inhaling, ingesting or having cutaneous contact with the phenoxy acid herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) or 2,4,5-trichlorophenoxyacetic acid (2,4,5-T);
- revising the factors in subsections 9(23) and 9(48) concerning inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD);
- new factors in subsections 9(24) and 9(49) concerning inhaling, ingesting or having cutaneous contact with a dioxin-like polychlorinated biphenyl;
- new factors in subsections 9(25) and 9(50) concerning inhaling ambient, chronically polluted air as specified;
- new definitions of 'albuminuria', 'ambient, chronically polluted air as specified', 'BMI', 'chronic kidney disease', 'clinically significant disorder of mental health as specified', 'cumulative equivalent dose', 'glucocorticoid therapy as specified', 'hyperuricaemia', 'inhaling, ingesting or having cutaneous contact with a dioxin-like polychlorinated biphenyl', 'MET', 'MRCA', 'paraganglioma', 'Specified List 1 of drugs', 'Specified List 2 of drugs', 'specified list of endocrine disorders' and 'VEA' in Schedule 1 - Dictionary;

**SUMMARY OF CHANGES**

		<ul style="list-style-type: none"> <li>• revising the definitions of 'being exposed to arsenic as specified', 'being overweight or obese', 'equivalent glucocorticoid therapy', 'equivalent inhaled glucocorticoid', 'high or very high potency topical glucocorticoid', 'inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD)', 'phaeochromocytoma' and 'relevant service' in Schedule 1 - Dictionary;</li> <li>• new table of specified drugs in Schedule 2 - Drugs; and</li> <li>• deleting the definitions of 'a chronic renal disease or injury', 'a clinically significant psychiatric disorder from the specified list', 'a drug from Specified List 2', 'a drug or a drug from a class of drugs from Specified List 1', 'a mildly strenuous level of physical activity', 'a specified antineoplastic drug', 'a specified endocrine related disorder', 'alcohol', 'chronic renal failure', 'having glucocorticoid therapy as specified' and 'phenoxy acid herbicide from the specified list'.</li> </ul> <p><b><i>For BoP SoP (Instrument No. 22/2022)</i></b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'hypertension' in subsection 7(2);</li> <li>• revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>• revising the factors in subsections 9(1) and 9(19) concerning being overweight or obese;</li> <li>• revising the factors in subsections 9(2) and 9(20) concerning consuming alcohol;</li> <li>• revising the factors in subsections 9(3) and 9(21) concerning consuming salt;</li> <li>• revising the factors in subsections 9(4) and 9(22) concerning having renal artery stenosis;</li> <li>• revising the factors in subsections 9(5) and 9(23) concerning having a solid organ, stem cell or bone marrow transplant;</li> <li>• new factors in subsections 9(6) and 9(24) concerning having diabetes mellitus;</li> <li>• revising the factors in subsections 9(7) and 9(25) concerning having chronic kidney disease;</li> <li>• revising the factors in subsections 9(8) and 9(26) concerning having an endocrine disorder;</li> <li>• revising the factors in subsections 9(9) and 9(27) concerning having sleep apnoea;</li> <li>• revising the factors in subsections 9(11) and 9(29) concerning having an aneurysm of the renal artery, an arteriovenous fistula involving the blood supply of the kidney, or an arteriovenous malformation involving the blood supply of the kidney;</li> <li>• new factors in subsections 9(12) and 9(30) concerning having a clinically significant disorder of mental health as specified;</li> <li>• revising the factors in subsections 9(13) and 9(31) concerning taking a drug from the Specified List 1 of drugs;</li> <li>• revising the factors in subsections 9(14) and 9(32) concerning taking a drug from the Specified List 2 of drugs</li> <li>• revising the factors in subsections 9(15) and 9(33) concerning having glucocorticoid therapy;</li> <li>• new factors in subsections 9(16) and 9(34) concerning taking medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection;</li> <li>• revising the factors in subsections 9(17) and 9(35) concerning inability to undertake any physical activity greater than 3 METs;</li> <li>• new factors in subsections 9(18) and 9(36) concerning being exposed to arsenic;</li> <li>• new definitions of 'albuminuria', 'being exposed to arsenic as specified', 'BMI', 'chronic kidney disease', 'clinically significant disorder of mental health as specified', 'glucocorticoid therapy as specified', 'MET', 'MRCA', 'paraganglioma', 'Specified List 1 of drugs', 'Specified List 2 of drugs', 'Specified List 3 of drugs', 'specified list of endocrine disorders' and 'VEA' in Schedule 1 - Dictionary;</li> <li>• revising the definitions of 'being overweight or obese', 'equivalent glucocorticoid therapy', 'equivalent inhaled glucocorticoid', 'high or very high potency topical glucocorticoid', 'phaeochromocytoma' and 'relevant service' in Schedule 1 - Dictionary; and</li> <li>• deleting the definitions of 'a chronic renal disease or injury', 'a drug from Specified List 2', 'a drug or a drug from a class of drugs from Specified List 1', 'a mildly strenuous level of physical activity', 'a specified antineoplastic drug', 'a specified endocrine related disorder', 'alcohol', 'chronic renal failure' and 'having glucocorticoid therapy as specified'.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>hypertension</i> as advertised in the Government Notices Gazette of 29 March 2021.</b></p>
23 & 24/2022	heart block	These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 9 March 2021 concerning <i>heart block</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

**SUMMARY OF CHANGES**

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

***For RH SoP (Instrument No. 23/2022)***

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'heart block' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- new factors in subsections 9(2) and 9(35) concerning having pulmonary thromboembolism;
- revising the factors in subsections 9(3) and 9(36) concerning having infiltration of the myocardium due to an infiltrative disease;
- new factors in subsections 9(4) and 9(37) concerning having cardiomyopathy;
- revising the factors in subsections 9(5) and 9(38) concerning having a benign or malignant neoplasm involving the heart;
- new factors in subsections 9(6) and 9(39) concerning having a lesion which compresses the atrioventricular node, bundle of His or the bundle branches of the heart;
- new factors in subsections 9(7) and 9(40) concerning having non-infectious myocarditis;
- new factors in subsections 9(8) and 9(41) concerning having viral myocarditis;
- revising the factors in subsections 9(9) and 9(42) concerning having a non-viral infection of the myocardium;
- revising the factors in subsections 9(10) and 9(43) concerning having infective endocarditis;
- revising the factors in subsections 9(11) and 9(44) concerning having a mineral or electrolyte abnormality;
- revising the factors in subsections 9(12) and 9(45) concerning taking a drug;
- revising the factors in subsections 9(13) and 9(46) concerning taking chloroquine or hydroxychloroquine;
- new factors in subsections 9(14) and 9(47) concerning having ingested a plant containing cardiac glycosides;
- new factors in subsections 9(15) and 9(48) concerning having acute pyrethroid poisoning after inhaling, ingesting or having cutaneous contact with a pyrethroid insecticide;
- revising the factors in subsections 9(16) and 9(49) concerning experiencing penetrating trauma to the heart;
- revising the factors in subsections 9(17) and 9(50) concerning having a thoracic surgical procedure or an invasive cardiac procedure;
- new factors in subsections 9(18) and 9(51) concerning experiencing a blunt chest injury;
- revising the factors in subsections 9(20) and 9(53) concerning having a bone marrow transplant by the inclusion of stem cell transplant;
- new factors in subsections 9(21) and 9(54) concerning having graft versus host disease after a bone marrow transplant or stem cell transplant;
- revising the factors in subsections 9(22) and 9(55) concerning undergoing a course of therapeutic radiation for cancer;
- revising the factors in subsections 9(23) and 9(56) concerning undertaking strenuous physical activity greater than 6 METs;
- revising the factors in subsections 9(26) and 9(59) concerning having hypertension;
- revising the factors in subsections 9(27) and 9(60) concerning having obstructive sleep apnoea;
- new factors in subsections 9(28) and 9(61) concerning having smoked cannabis products;
- new factors in subsections 9(29) and 9(62) concerning binge drinking;
- new factors in subsections 9(30) and 9(63) concerning having a thyroid condition;
- revising the factors in subsections 9(31) and 9(64) concerning having an autoimmune disease;
- new factors in subsections 9(32) and 9(65) concerning having acute rheumatic fever;
- new factors in subsections 9(33) and 9(66) concerning having rheumatic heart disease;
- deleting the factors concerning having myocarditis as these are now covered by factors in subsections 9(7) and 9(40) concerning having non-infectious myocarditis, and factors in subsections 9(8) and 9(41) concerning having viral myocarditis;
- deleting the factors concerning experiencing a powerful, non-penetrating blow to the chest, resulting in injury warranting medical attention, as these are now covered by the factors in subsections 9(18) and 9(51) concerning experiencing a blunt chest injury;
- deleting the factors concerning having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the heart, as these are now covered by the factors in subsections 9(22) and 9(55) concerning undergoing a course of therapeutic radiation for cancer;

**SUMMARY OF CHANGES**

- new definitions of 'binge drinking', 'blunt chest injury', 'MRCA', 'specified list of autoimmune diseases', 'specified list of drugs', 'specified list of infiltrative diseases', 'specified list of mineral or electrolyte abnormalities', 'specified list of thyroid conditions' and 'VEA' in Schedule 1 - Dictionary;
- revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'a specified autoimmune disease', 'a specified mineral or electrolyte abnormality', 'an organism from the specified list' and 'cumulative equivalent dose'.

***For BoP SoP (Instrument No. 24/2022)***

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'heart block' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- new factors in subsections 9(2) and 9(29) concerning having pulmonary thromboembolism;
- revising the factors in subsections 9(3) and 9(30) concerning having infiltration of the myocardium due to amyloidosis or sarcoidosis;
- new factors in subsections 9(4) and 9(31) concerning having cardiomyopathy;
- revising the factors in subsections 9(5) and 9(32) concerning having a benign or malignant neoplasm involving the heart;
- new factors in subsections 9(6) and 9(33) concerning having a lesion which compresses the atrioventricular node, bundle of His or the bundle branches of the heart;
- new factors in subsections 9(7) and 9(34) concerning having non-infectious myocarditis;
- new factors in subsections 9(8) and 9(35) concerning having viral myocarditis;
- revising the factors in subsections 9(9) and 9(36) concerning having a non-viral infection of the myocardium;
- revising the factors in subsections 9(10) and 9(37) concerning having infective endocarditis;
- revising the factors in subsections 9(11) and 9(38) concerning having a mineral or electrolyte abnormality;
- revising the factors in subsections 9(12) and 9(39) concerning taking a drug;
- revising the factors in subsections 9(13) and 9(40) concerning taking chloroquine or hydroxychloroquine;
- new factors in subsections 9(14) and 9(41) concerning having ingested a plant containing cardiac glycosides;
- revising the factors in subsections 9(15) and 9(42) concerning experiencing penetrating trauma to the heart;
- revising the factors in subsections 9(16) and 9(43) concerning having a thoracic surgical procedure or an invasive cardiac procedure;
- new factors in subsections 9(17) and 9(44) concerning experiencing a blunt chest injury;
- revising the factors in subsections 9(19) and 9(46) concerning having a bone marrow transplant by the inclusion of stem cell transplant;
- new factors in subsections 9(20) and 9(47) concerning having graft versus host disease after a bone marrow transplant or stem cell transplant;
- revising the factors in subsections 9(21) and 9(48) concerning undergoing a course of therapeutic radiation for cancer;
- revising the factors in subsections 9(22) and 9(49) concerning undertaking strenuous physical activity greater than 6 METs;
- revising the factors in subsections 9(24) and 9(51) concerning having hypertension;
- revising the factors in subsections 9(25) and 9(52) concerning having an autoimmune disease;
- new factors in subsections 9(26) and 9(53) concerning having acute rheumatic fever;
- new factors in subsections 9(27) and 9(54) concerning having rheumatic heart disease;
- deleting the factors concerning having myocarditis as these are now covered by factors in subsections 9(7) and 9(34) concerning having non-infectious myocarditis, and factors in subsections 9(8) and 9(35) concerning having viral myocarditis;
- deleting the factors concerning experiencing a powerful, non-penetrating blow to the chest, resulting in injury warranting medical attention, as these are now covered by the factors in subsections 9(17) and 9(44) concerning experiencing a blunt chest injury;
- deleting the factors concerning having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the heart, as these are now covered by the factors in subsections 9(21) and 9(48) concerning undergoing a course of therapeutic radiation for cancer;
- deleting the factors concerning being envenomated by a scorpion or snake;

SUMMARY OF CHANGES		
		<ul style="list-style-type: none"> <li>new definitions of 'blunt chest injury', 'MRCA', 'specified list of autoimmune diseases', 'specified list of drugs', 'specified list of mineral or electrolyte abnormalities' and 'VEA' in Schedule 1 - Dictionary;</li> <li>revising the definition of 'relevant service' in Schedule 1 - Dictionary; and</li> <li>deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'a specified autoimmune disease', 'a specified mineral or electrolyte abnormality', 'an organism from the specified list' and 'cumulative equivalent dose'.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>heart block</i> as advertised in the Government Notices Gazette of 9 March 2021.</b></p>
25 & 26/2022	periodontal abscess	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>periodontal abscess</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p><b>For RH and BoP SoPs (Instrument Nos. 25 &amp; 26/2022)</b></p> <ul style="list-style-type: none"> <li>adopting the latest revised Instrument format, which commenced in 2015;</li> <li>specifying a day of commencement for the Instrument in section 2;</li> <li>revising the definition of 'periodontal abscess' in subsection 7(2);</li> <li>revising the factors in subsections 9(2) and 9(6) concerning having a foreign body embedded in the affected region of the periodontium, by the inclusion of a note;</li> <li>revising the factors in subsections 9(3) and 9(7) concerning having trauma to the affected region of the periodontium, by the inclusion of a note;</li> <li>new factors in subsections 9(4) and 9(8) concerning having surgery to the affected region of the periodontium;</li> <li>deleting the factors concerning having dental pulp disease of a tooth in the affected region of the periodontium;</li> <li>new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary;</li> <li>revising the definitions of 'relevant service' and 'trauma to the affected region of the periodontium' in Schedule 1 - Dictionary; and</li> <li>deleting the definition of 'a foreign body'.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>periodontal abscess</i> as advertised in the Government Notices Gazette of 5 January 2021.</b></p>
27 & 28/2022	periodontitis	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>periodontitis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p><b>For RH SoP (Instrument No. 27/2022)</b></p> <ul style="list-style-type: none"> <li>adopting the latest revised Instrument format, which commenced in 2015;</li> <li>specifying a day of commencement for the Instrument in section 2;</li> <li>revising the definition of 'periodontitis' in subsection 7(2);</li> <li>revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>revising the factors in subsections 9(1) and 9(17) concerning having gingivitis involving the affected region of the periodontium;</li> <li>revising the factors in subsections 9(2) and 9(18) concerning having a foreign body in contact with the affected region of the periodontium;</li> <li>revising the factors in subsections 9(3) and 9(19) concerning having an oral piercing adjacent to the affected region of the periodontium, by the inclusion of a note;</li> <li>revising the factors in subsections 9(4) and 9(20) concerning having trauma to the affected region of the periodontium, by the inclusion of a note;</li> <li>new factors in subsections 9(5) and 9(21) concerning having surgery to the affected region of the periodontium;</li> <li>revising the factors in subsections 9(6) and 9(22) concerning having neutropenia or agranulocytosis;</li> <li>revising the factors in subsections 9(7) and 9(23) concerning having leukaemia;</li> <li>revising the factors in subsections 9(8) and 9(24) concerning having infection with human immunodeficiency virus;</li> </ul>

**SUMMARY OF CHANGES**

- revising the factors in subsections 9(10) and 9(26) concerning being obese;
- revising the factors in subsections 9(11) and 9(27) concerning having chronic renal failure;
- revising the factors in subsections 9(12) and 9(28) concerning having an autoimmune disease;
- revising the factors in subsections 9(13) and 9(29) concerning having smoked tobacco products;
- new factors in subsections 9(14) and 9(30) concerning having severe malnutrition;
- new factors in subsections 9(15) and 9(31) concerning having severe vitamin C deficiency or vitamin D deficiency;
- new factors in subsections 9(16) and 9(32) concerning consuming alcohol;
- deleting the factors concerning having rheumatoid arthritis or ankylosing spondylitis, as these are now covered by the factors in subsections 9(12) and 9(28) concerning having an autoimmune disease;
- deleting the factors concerning having a nutritional deficiency as these are now covered by the factors in subsections 9(14) and 9(30) concerning having severe malnutrition and the factors in subsections 9(15) and 9(31) concerning having severe vitamin C deficiency or vitamin D deficiency;
- deleting the factors concerning smoking cannabis;
- new definitions of 'BMI', 'chronic renal failure', 'MRCA', 'one pack-year', 'severe vitamin C deficiency', 'specified list of autoimmune diseases', 'VEA' and 'vitamin D deficiency' in Schedule 1 - Dictionary;
- revising the definitions of 'being obese', 'oral piercing', 'relevant service' and 'trauma to the affected region of the periodontium' in Schedule 1 - Dictionary; and
- deleting the definitions of 'a foreign body', 'a nutritional deficiency', 'alcohol' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.

***For BoP SoP (Instrument No. 28/2022)***

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'periodontitis' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factors in subsections 9(1) and 9(17) concerning having gingivitis involving the affected region of the periodontium;
- new factor in subsection 9(2) concerning having a foreign body in contact with the affected region of the periodontium, for clinical onset;
- revising the factors in subsections 9(3) and 9(19) concerning having an oral piercing adjacent to the affected region of the periodontium, by the inclusion of a note;
- revising the factors in subsections 9(4) and 9(20) concerning having trauma to the affected region of the periodontium;
- new factors in subsections 9(5) and 9(21) concerning having surgery to the affected region of the periodontium;
- revising the factors in subsections 9(6) and 9(22) concerning having neutropenia or agranulocytosis;
- revising factors in subsections 9(7) and 9(23) concerning having leukaemia;
- revising the factors in subsections 9(8) and 9(24) concerning having infection with human immunodeficiency virus;
- revising the factors in subsections 9(10) and 9(26) concerning being obese;
- revising the factors in subsections 9(11) and 9(27) concerning having chronic renal failure;
- revising the factors in subsections 9(12) and 9(28) concerning having rheumatoid arthritis by the inclusion of inflammatory bowel disease;
- revising the factors in subsections 9(13) and 9(29) concerning having smoked tobacco products;
- new factors in subsections 9(14) and 9(30) concerning having severe malnutrition;
- new factors in subsections 9(15) and 9(31) concerning having severe vitamin C deficiency or vitamin D deficiency;
- new factors in subsections 9(16) and 9(32) concerning consuming alcohol;
- revising the factor in subsection 9(18) concerning having a foreign body in contact with the affected region of the periodontium, for clinical worsening;
- deleting the factor concerning having an osseointegrated implant or dental prosthesis, including single crowns, fixed partial dentures, all-ceramic crowns, resin-bonded prostheses or posts and cores, embedded in the affected region of the periodontium, for clinical onset, as this is now covered by the factor in subsection 9(2) concerning having a foreign body in contact with the affected region of the periodontium;



SUMMARY OF CHANGES		
		<ul style="list-style-type: none"> <li>deleting the factors concerning having a nutritional deficiency as these are now covered by the factors in subsections 9(14) and 9(30) concerning having severe malnutrition and the factors in subsections 9(15) and 9(31) concerning having severe vitamin C deficiency or vitamin D deficiency;</li> <li>new definitions of 'BMI', 'chronic renal failure', 'MRCA', 'one pack-year', 'severe vitamin C deficiency', 'VEA' and 'vitamin D deficiency' in Schedule 1 - Dictionary;</li> <li>revising the definitions of 'being obese', 'oral piercing', 'relevant service' and 'trauma to the affected region of the periodontium' in Schedule 1 - Dictionary; and</li> <li>deleting the definitions of 'a foreign body', 'a nutritional deficiency', 'alcohol' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>periodontitis</i> advertised in the Government Notices Gazette of 5 January 2021.</b></p>
29 & 30/2022	eosinophilic oesophagitis	<p><b>New Condition</b></p> <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 12 October 2021 concerning <i>eosinophilic oesophagitis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence available to the Authority.</p> <p><b>The determining of these new Instruments finalises the investigation in relation to <i>eosinophilic oesophagitis</i> as advertised in the Government Notices Gazette of 12 October 2021.</b></p>
31 & 32/2022	exertional heat illness	<p><b>New Condition</b></p> <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 12 October 2021 concerning <i>heat stroke</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence available to the Authority.</p> <p><b>The determining of these new Instruments finalises the investigation in relation to <i>heat stroke</i> as advertised in the Government Notices Gazette of 12 October 2021.</b></p>
33 & 34/2022	vaccine-induced thrombotic thrombocytopenia	<p><b>New Condition</b></p> <p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 2 November 2021 concerning <i>thrombosis with thrombocytopenia syndrome</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence available to the Authority.</p> <p><b>The determining of these new Instruments finalises the investigation in relation to <i>thrombosis with thrombocytopenia syndrome</i> as advertised in the Government Notices Gazette of 2 November 2021.</b></p>
35 & 36/2022	suicide and attempted suicide	<p><b>Amendment</b></p> <p>These instruments amend Statements of Principles Nos. 65 and 66 of 2016 concerning <i>suicide and attempted suicide</i> by:</p> <p><b><i>For RH and BoP SoPs (Instrument Nos. 65 and 66/2016)</i></b></p> <ul style="list-style-type: none"> <li>revising the definition of 'clinically significant disorder of mental health as specified' in Schedule 1 - Dictionary.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>suicide and attempted suicide</i> as advertised in the Government Notices Gazette of 2 November 2021.</b></p>